ARGX News & Analysis
2 articles
Market Mood
Argenx (ARGX) Reports $830.79 Share Price with 23.10% Annual Growth
Argenx SE (NASDAQ:ARGX) closed at $830.79 per share on August 3, 2026. The company's market capitalization stands at $51.66 billion, with a 52-week trading range between $631.47 and $953.58. Over the past month, shares have decreased by 9.69%, but they gained 23.10% over the last year. The Baron Health Care Fund highlighted optimism around upcoming clinical readouts for its product Vyvgart, demonstrating potential efficacy across various autoimmune conditions. This is significant as it indicates ongoing investor interest and potential for growth in Argenx's treatments, which may ultimately benefit investors.
Read More: Argenx (ARGX) Reports $830.79 Share Price with 23.10% Annual Growth
argenx (ARGX) Stock Rating Reiterated Amid Myositis Trial Update
H.C. Wainwright has maintained its rating on argenx (ARGX) following updates on a clinical trial related to myositis. While specific figures or data from the trial were not disclosed, the reiteration of the stock rating indicates confidence in ARGX's developments. This is significant as positive trial outcomes can lead to increased investor interest and potentially affect the stock price. Monitoring the ongoing trial results will be crucial for gauging market reaction and company valuation in the coming months.
Read More: argenx (ARGX) Stock Rating Reiterated Amid Myositis Trial Update